Understand the source comparison
Best Peptides for Bladder Health: Mechanism Comparison
Thymosin Beta-4 Actin sequestration, VEGF upregulation, urothelial regeneration Epithelial damage, barrier dysfunction, IC Strong preclinical (mouse, rat models); Phase I human trials underway Subcutaneous injection Best evidence for tissue repair and barrier
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Beta-4
- Actin sequestration, VEGF upregulation, urothelial regeneration
- Epithelial damage, barrier dysfunction, IC
- Strong preclinical (mouse, rat models); Phase I human trials underway
- Subcutaneous injection
- Best evidence for tissue repair and barrier restoration. First-line consideration for compromised urothelium
- BPC-157
- Growth hormone receptor activation, VEGFR2 upregulation, angiogenesis
- Acute injury, post-surgical healing, chronic inflammation
- Moderate preclinical; no Phase III human data
- Subcutaneous or intravesical
- Accelerates healing in injury models. Most useful post-procedure or after acute inflammatory episodes
- KPV (Lys-Pro-Val)
- NF-κB inhibition, mast cell stabilisation, cytokine suppression
- Chronic cystitis, mast cell-mediated pain, IC flares
- Moderate preclinical; limited human data
- Subcutaneous or oral (low bioavailability orally)
- Potent anti-inflammatory without immune suppression. Best for acute symptom management during flare-ups
- Dihexa
- HGF receptor agonism, neuroplasticity, synaptic remodeling
- Neurogenic bladder, spinal injury, diabetic neuropathy
- Moderate preclinical; Phase I human trials (non-bladder indications)
- Long-term neuroplasticity pathway. Requires 8–12 weeks to show effect; not for acute use
- Cerebrolysin
- BDNF/CNTF delivery, axonal sprouting, nerve regeneration
- Neurogenic dysfunction, peripheral neuropathy
- Strong preclinical (CNS models); limited bladder-specific data
- Intramuscular or IV infusion
- Proven in CNS injury. Bladder application is extrapolated from peripheral nerve data; promising but early-stage
- Thymalin
- T-regulatory modulation, immune tolerance, mast cell reduction
- Autoimmune cystitis, IC, recurrent UTI
- Moderate clinical (Russian trials); minimal Western data
- Long-term immune reset. Reduces flare frequency over months; not for acute relief